Lab Study of MQX-503 in Treatment of Raynaud's
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00253331|
Recruitment Status : Completed
First Posted : November 15, 2005
Last Update Posted : May 30, 2007
The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in the determination of finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to cold temperatures.
Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a cold chamber, and then blood flow and skin temperature are monitored for the next two hours.
Each patient will receive multiple doses on different days so that each can serve as his/her own control in interpreting the response.
|Condition or disease||Intervention/treatment||Phase|
|Raynaud Disease Raynaud Disease Secondary to Scleroderma Raynaud Secondary to Other Autoimmune Disease||Drug: topical organogel with nitroglycerin||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||36 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon|
|Study Start Date :||November 2004|
|Study Completion Date :||September 2005|
- Differntial time for blood flow to return to baseline following cold exposure.
- Differential time for skin temperature to return to baseline following cold exposure.
- Quantitative reduction or prevention in symptoms following cold exposure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00253331
|United States, Maryland|
|Johns Hopkins Bayview Medical Center|
|Baltimore, Maryland, United States, 21224|
|United States, Washington|
|University of Washington Medical College|
|Seattle, Washington, United States, 98195|
|Principal Investigator:||Laura K Hummers, MD||Johns Hopkins University|
|Principal Investigator:||Carin Dugowson, MD, MPH||University of Washington Medical College|